Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals (NCT02933970), a randomized na study. The primary outcome is Observed Percentage of Patients in Both Arms Who Achieve Viral Eradication.

2. Clinical Question

The trial asks whether locating specialist HCV care within the OAT setting through telemedicine is associated with a different rate of viral eradication than referral-based care. Its stated comparison concerns both a patient-centered outcome and a clinical outcome: achieving undetectable HCV RNA after treatment. The registry describes the primary measure as the observed percentage in both arms, but does not report arm-specific percentages, participant counts achieving the endpoint, an effect estimate, or a statistical test. The relative results therefore cannot be determined from the registry record.

The care pathways differ in where and how specialist management is delivered. In the intervention arm, care is on site and uses video conferencing. In the control arm, participants are referred to an off-site liver specialist. The registry’s summary anticipates that usual care will in most cases involve an off-site referral; the arm description specifies referral. The record does not report further details about the care received after referral or the precise implementation of telemedicine across the programs.

3. Trial Design

This was a completed randomized, stepped-wedge trial with a crossover model and no masking. The registry identifies the design as cluster-randomized. The intervention was compared with usual care for HCV management among participants receiving OAT. The record lists an enrollment of 602 and identifies 12 opioid treatment programs throughout New York State as the setting for the primary-outcome population.

The two care strategies were organized around the OAT program. Participants in the intervention arm were treated on site by a liver specialist through two-way video conferencing. Participants in the control arm were referred to an off-site liver specialist. Both descriptions concern HCV-seropositive people enrolled in an OAT program for at least 12 months. The registry identifies the intervention type as “Other,” and gives no further operational details about the delivery of usual care.

In a stepped-wedge cluster-randomized design, clusters are assigned to sequences in which they move between control and intervention conditions over time; this is a general description of the design label, not a description of the specific schedule used in this trial. The registry does not report the number or timing of steps, the order in which programs changed conditions, or the allocation procedure. The crossover label likewise does not establish the exact schedule or the handling of participants who experienced more than one care condition. Those details are not reported in the registry record.

The trial started on 2017-02-28, reached primary completion on 2020-10-01, and is listed as completed. Its phase is recorded as NA. The registry record does not report a masking procedure beyond identifying the study as having no masking. It also does not report the planned analysis approach for the clustered and stepped-wedge structure, or explain how time trends were to be handled. No numerical primary-outcome results or analysis estimates are reported, so the completed status should not be read as evidence of a particular treatment effect.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Step 1: Months 0-9

Step 2: Months 10-18

Step 3: Months 19-27

Period 4: Mos 28-36

Analysis population for the primary outcome, as defined in the registry: Participants enrolled from 12 opioid treatment programs throughout New York State

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Observed Percentage of Patients in Both Arms Who Achieve Viral Eradication, measured over 12 weeks post treatment cessation.

The primary endpoint is viral eradication, assessed 12 weeks after treatment cessation. The registry defines eradication as undetectable HCV RNA at that time. The measure is described as the observed percentage of patients in both arms who achieve eradication, with participants as the unit. It is therefore a binary outcome at the participant level: each participant either meets the stated definition at the assessment time or does not.

This endpoint captures whether the intended virologic outcome is present after the treatment course has ended, rather than merely whether treatment was started or completed. The registry separately lists treatment initiation percentages, treatment completion rates, and patient satisfaction as secondary outcomes. These measures address different stages and aspects of care; they do not replace the primary measure of viral eradication.

The registry identifies the outcome timeframe and definition but does not report the number assessed, the number who achieved eradication, arm-specific percentages, or an estimate comparing the arms. It also does not state how participants without an HCV RNA result at the assessment time were handled. Without those outcome and analysis details, the endpoint can be described but its observed frequency or comparative result cannot be interpreted from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a randomized, cluster-randomized, stepped-wedge trial with a crossover model and no masking. These labels describe important design features, but the record does not provide the analysis plan or numerical results. The endpoint is binary at the participant level: viral eradication is defined as undetectable HCV RNA 12 weeks after treatment cessation. The registry does not report the number of participants meeting that definition in either arm.

Why does clustering matter?

General statistical explanation: In a cluster-randomized study, groups rather than individual participants are assigned to care conditions. Outcomes among participants in the same group can be correlated. When that correlation is present, the amount of independent information is less than it would be if every participant contributed an unrelated observation. An analysis that ignores clustering can therefore misstate the precision of an estimate. The registry itself cautions that a simple individual-level re-analysis would be misleading.

For this trial, the primary-outcome population is described as participants enrolled from 12 opioid treatment programs throughout New York State. The record does not identify the exact randomization unit in detail, report how many programs followed each sequence, or describe the statistical method used to account for within-program correlation. It also does not provide a cluster-adjusted effect estimate or its uncertainty. No numerical recalculation is warranted from the information in the registry record.

What does the stepped-wedge label imply?

General statistical explanation: A stepped-wedge design typically introduces an intervention to clusters in a planned sequence, so clusters contribute observations under different conditions over time. The timing of exposure can matter because outcomes may change over calendar time for reasons unrelated to the intervention. Analysis may therefore need to distinguish intervention effects from time effects and account for the cluster structure. These are general considerations, not claims about the specific model used in this trial.

The registry identifies the study as stepped-wedge and crossover, but does not report the timing of transitions, the sequence of implementation, the duration of periods, or the approach to time adjustment. It does not state whether or how participant exposure across conditions was handled. The design labels alone are not enough to reconstruct the analysis.

How should an estimate and confidence interval be read?

General statistical explanation: An effect estimate describes the contrast between groups according to a chosen scale, while a confidence interval expresses the uncertainty around that estimate under the model used. For a binary outcome such as viral eradication, analysts may choose different scales for the contrast. The scale and model influence the estimate’s interpretation. The registry record does not report an effect estimate, confidence interval, selected scale, or model, so none can be interpreted for this trial.

A p-value, if reported, would address how compatible the observed data are with a specified null hypothesis under the analysis assumptions; it would not by itself describe the size or practical importance of an effect. No p-value or hypothesis-test result is reported in the registry record. The endpoint definition and enrollment figure do not allow one to recover an unreported test result.

What can be inferred from the planning assumptions?

The registry describes a planning illustration based on a two-sided significance level of 0.05, equal allocation between arms, a normal approximation, and an effect to detect defined as a stated fraction of the observed effect. It says that the illustration is not the trial’s own design. Such planning values are hypothetical sample-size illustrations, not results and not observed power. The registry record does not report the trial’s sample-size justification or numerical planning outputs. In particular, planning assumptions cannot be treated as evidence about the trial’s observed effect or precision.

The record lists 602 participants as the enrollment and states that no analysis entries are present. Enrollment is not the same as the number with an endpoint assessment, and it does not disclose how many participants were analyzed. The record does not provide arm-specific endpoint denominators, missing-data methods, model diagnostics, or sensitivity analyses. Those details are necessary to evaluate the assumptions behind any comparative estimate, but they are not reported in the registry record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Control", "Intervention")
n      <- c(312, 290)
events <- c(106, 246)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Control  312  106  34.0  28.7  39.5  28.9  39.4  28.9  39.4
ARM  Intervention  290  246  84.8  80.2  88.8  80.2  88.5  80.2  88.5

11. Multiplicity, Missing Data and Analysis Populations

The registry names three secondary outcomes: comparison of treatment initiation percentages, treatment completion rates, and patient satisfaction. It also describes viral eradication as the primary outcome. The record does not report results for these outcomes, the number of outcome comparisons included in a planned testing strategy, or any approach to multiplicity. It is therefore not possible to determine whether the sponsor adjusted for multiple comparisons or designated which analyses would be confirmatory.

Missing-data handling is not reported in the registry record. The primary endpoint requires an HCV RNA assessment 12 weeks after treatment cessation, but the record does not state how participants without an assessment were classified or whether missing outcomes were excluded, imputed, or addressed through sensitivity analyses. It also does not report the number of participants with missing endpoint data in either arm.

The analysis populations are not described. The record does not specify whether the primary comparison followed randomized assignment, included only participants who initiated treatment, or used another population definition. It does not report exclusions from analysis or reasons for them. Because the study is cluster-randomized and stepped-wedge, the handling of participants and programs across conditions is particularly relevant; the details are not reported.

The record lists no analysis entries. Thus, neither multiplicity control nor missing-data and analysis-population decisions can be evaluated from the registry information. The absence of these details does not establish that no such methods were used; it means they are not reported in the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The registry’s adverse-event entries list 312 participants at risk in the control group and 290 in the intervention group. The serious adverse-event entries report zero affected participants in each group. The entries for other adverse events also report zero affected participants in each group. Deaths are listed as 3 in the control group and 9 in the intervention group.

These figures should be read as registry counts, not as evidence that one care strategy caused or prevented an event. The record does not describe causes of death, timing, relatedness to treatment, event definitions beyond the serious and other categories, or how events were collected. It also does not provide participant-level follow-up time or an analysis comparing safety outcomes between groups. Counts alone do not establish a causal difference, particularly in a cluster-randomized, stepped-wedge study.

The entries report affected participants, not the total number of events, and the registry does not give further detail about event types. The listed deaths should not be assumed to be related to HCV treatment or to the telemedicine approach. The record does not report such an attribution. The adverse-event figures are therefore limited descriptive information, not a complete safety analysis.

13. What the Result Does, and Does Not, Mean

The registry record establishes the clinical question, the care pathways, and the primary endpoint definition. It describes a comparison of on-site, video-based liver specialist care integrated with OAT against referral to an off-site liver specialist. It identifies viral eradication, defined by undetectable HCV RNA 12 weeks after treatment cessation, as the primary outcome. It also lists treatment initiation, treatment completion, and patient satisfaction as secondary outcomes.

What the record does not establish is the comparative outcome. No arm-specific eradication percentages, endpoint counts, effect estimate, confidence interval, or p-value are reported. The record therefore does not show whether either arm had a higher observed rate, the magnitude of any difference, or the precision of a comparison. It cannot support a conclusion that telemedicine improved, worsened, or had no effect on the primary endpoint.

The trial’s completed status and enrollment of 602 describe trial administration, not the endpoint result. Likewise, the adverse-event counts do not answer the effectiveness question and do not establish a causal safety comparison. The record does not report enough detail to assess missing endpoint data, analysis populations, time effects, or the method used to account for clustering.

This distinction matters because a registry record can describe a planned or completed study without presenting a complete results analysis. An endpoint definition tells readers what was intended to be measured; it does not reveal the observed outcome. Without the sponsor’s analysis and its uncertainty estimates, there is no basis for interpreting the comparative evidence from this record. The appropriate reading is that the primary result and the secondary findings are not reported in the registry record, not that the trial found no difference.

14. Why This Trial Matters Statistically

The trial raises a statistical question that is not captured by a simple comparison of participant counts: how to estimate a care effect when programs, rather than just individuals, are involved and intervention status changes within a stepped-wedge design. Participants in the same OAT program may share implementation conditions, and the timing of a program’s transition can coincide with broader time trends. General statistical practice must address these features to obtain appropriately calibrated estimates and uncertainty.

The registry explicitly warns that a simple individual-level re-analysis would be misleading. That caution is important because an analysis that ignores clustering may overstate the amount of independent information. For stepped-wedge designs, accounting for time and sequence can also affect the estimated contrast. The registry does not report the sponsor’s model or its assumptions, so readers cannot assess how these issues were addressed.

The endpoint is clinically interpretable as a defined post-treatment virologic outcome, while initiation and completion outcomes can describe earlier points in the care pathway. Considering these outcomes together could help distinguish whether differences arise in access, treatment delivery, or endpoint achievement, but the registry record reports no findings for any of them. The design and outcome choices therefore show what the study set out to evaluate, while the missing analyses prevent statistical conclusions about what it observed.

For biostatistical readers, this record is a reminder that design labels, enrollment, and endpoint definitions are not substitutes for an analysis estimate with its uncertainty and denominator. Transparent reporting of cluster structure, time adjustment, missing-data handling, analysis populations, and multiplicity decisions is needed to judge the strength and scope of a trial’s conclusions. Those details are not reported in the registry record.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpretation is the absence of numerical outcome results. Although viral eradication is clearly defined, no arm-specific outcome values or comparative analysis are reported. There are likewise no results for the secondary outcomes. The completed status does not resolve this absence.

The registry identifies a cluster-randomized, stepped-wedge design and a crossover model, and it cautions against simple individual-level re-analysis. Yet it does not describe the allocation sequence, transition timing, program-level data structure, or statistical model. The record therefore does not allow an independent assessment of the design’s implementation or of how clustering and time were handled.

The endpoint definition specifies assessment 12 weeks after treatment cessation, but there is no report of endpoint denominators, missing assessments, or the approach to participants without a result. The analysis population and exclusions are also not reported. These gaps prevent evaluation of how complete or representative the endpoint data were.

The record does not report a sample-size justification, interim analyses, a detailed statistical analysis plan, or multiplicity handling. It describes planning assumptions for an illustration, but not numerical planning outputs. These assumptions cannot be used to infer observed power or recover the missing treatment effect. Finally, the adverse-event entries provide counts without event descriptions, relatedness, timing, or comparative analysis. These limitations apply to what can be concluded from the registry record and do not establish whether further analyses exist elsewhere.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals — NCT02933970.
• Registry record last updated 2024-12-20; status last verified 2024-12.
• Results first posted 2024-12-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT02933970 is a completed, randomized, cluster-randomized stepped-wedge trial with a crossover model and no masking. It enrolled 602 participants and compared OAT-integrated telemedicine HCV management with referral to an off-site liver specialist. The trial started on 2017-02-28 and reached primary completion on 2020-10-01.

The primary endpoint was viral eradication, defined as undetectable HCV RNA 12 weeks after treatment cessation, among participants enrolled from 12 opioid treatment programs throughout New York State. Secondary outcomes concerned treatment initiation, treatment completion, and patient satisfaction. The registry record reports no numerical primary or secondary outcome results and no analysis estimates. It also does not report methods for missing data, analysis populations, multiplicity, or the handling of clustering and time in the analysis.